These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 2208115

  • 41. The effect of vinca alkaloids in enhancing the sensitivity of a methotrexate-resistant (L1210/R7A) line, studied by flow cytometric and chromosome number analysis.
    McGown AT, Poppitt DG, Swindell R, Fox BW.
    Cancer Chemother Pharmacol; 1984; 13(1):47-53. PubMed ID: 6733842
    [Abstract] [Full Text] [Related]

  • 42. Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells.
    Van Belle SJ, De Smet MC, De Mey JE, Storme GA.
    Anticancer Res; 1991; 11(1):465-71. PubMed ID: 2018383
    [Abstract] [Full Text] [Related]

  • 43. Cellular uptake and tubulin binding properties of four Vinca alkaloids.
    Singer WD, Himes RH.
    Biochem Pharmacol; 1992 Feb 04; 43(3):545-51. PubMed ID: 1540212
    [Abstract] [Full Text] [Related]

  • 44. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
    Zhang CC, Yang JM, Bash-Babula J, White E, Murphy M, Levine AJ, Hait WN.
    Cancer Res; 1999 Aug 01; 59(15):3663-70. PubMed ID: 10446979
    [Abstract] [Full Text] [Related]

  • 45. Growth inhibitory activity of S12363, a novel vinca alkaloid derivative on human melanoma cell lines.
    Tolis C, Photiou A, Camplejohn RS, Retsas S.
    Anticancer Res; 1993 Aug 01; 13(1):161-6. PubMed ID: 8476208
    [Abstract] [Full Text] [Related]

  • 46. Cytotoxicity, cell cycle kinetics and morphonuclear-induced effects of Vinca alkaloid anticancer agents.
    Pauwels O, Kiss R, Pasteels JL, Atassi G.
    J Pharm Pharmacol; 1995 Oct 01; 47(10):870-5. PubMed ID: 8583358
    [Abstract] [Full Text] [Related]

  • 47. Correlation of cytotoxicity and mitotic spindle dissolution by vinblastine in mammalian cells.
    Tucker RW, Owellen RJ, Harris SB.
    Cancer Res; 1977 Dec 01; 37(12):4346-51. PubMed ID: 922725
    [Abstract] [Full Text] [Related]

  • 48. Preclinical and clinical pharmacology of vinca alkaloids.
    Zhou XJ, Rahmani R.
    Drugs; 1992 Dec 01; 44 Suppl 4():1-16; discussion 66-9. PubMed ID: 1283846
    [Abstract] [Full Text] [Related]

  • 49. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
    Houghton JA, Williams LG, Dodge RK, George SL, Hazelton BJ, Houghton PJ.
    Biochem Pharmacol; 1987 Jan 01; 36(1):81-8. PubMed ID: 3541941
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Vinca alkaloids enhance the half-life of tumour ornithine decarboxylase.
    Morata P, Jiménez-Mesa J, Núñez de Castro I, Sánchez-Jiménez FM.
    Cancer Lett; 1994 Jun 30; 81(2):209-13. PubMed ID: 8012939
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics.
    Bradford R, Koppel H, Pilkington GJ, Thomas DG, Darling JL.
    J Neurooncol; 1997 Sep 30; 34(3):247-61. PubMed ID: 9258817
    [Abstract] [Full Text] [Related]

  • 54. Relationship between the cellular accumulation and the cytotoxicity of S12363, a new Vinca alkaloid derivative.
    Pierré A, Pérez V, Léonce S, Boutin JA, Saint-Dizier D, Hautefaye P, Lavielle G, Atassi G.
    Cancer Chemother Pharmacol; 1992 Sep 30; 29(5):367-74. PubMed ID: 1551175
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Chemistry and mode of action of vinca alkaloids].
    Wilms K.
    Planta Med; 1972 Nov 30; 22(3):324-33. PubMed ID: 4649588
    [No Abstract] [Full Text] [Related]

  • 57. Cellular pharmacology of Vinca alkaloid resistance and its circumvention.
    Beck WT.
    Adv Enzyme Regul; 1984 Nov 30; 22():207-27. PubMed ID: 6089511
    [Abstract] [Full Text] [Related]

  • 58. In vitro sensitivity of normal granulocytic and lymphoma colonies to vinca alkaloids.
    Smith SD, Trueworthy RC, Kisker SE, Noller LG, Lowman JT.
    Cancer; 1983 Feb 01; 51(3):417-22. PubMed ID: 6600412
    [Abstract] [Full Text] [Related]

  • 59. Synthesis of vinca alkaloids and related compounds, Part XCVI. Nitration study of vinblastine-type bisindole alkaloids.
    Szabó L, Bölcskei H, Eszter BG, Mák M, Szántay C.
    Arch Pharm (Weinheim); 2001 Dec 01; 334(12):399-405. PubMed ID: 11852536
    [Abstract] [Full Text] [Related]

  • 60. Cytotoxicity of Vinca minor.
    Khanavi M, Pourmoslemi S, Farahanikia B, Hadjiakhoondi A, Ostad SN.
    Pharm Biol; 2010 Jan 01; 48(1):96-100. PubMed ID: 20645762
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.